<DOC>
	<DOCNO>NCT01653600</DOCNO>
	<brief_summary>The nitinol stent proven superior primary patency balloon angioplasty superficial femoral artery lesion . Recent stent design improvement focus decrease stent fracture rate negatively impact patency rate rearrange strut alignment . In literature , however , prospective , randomize , control , clinical trial comparison stent fracture primary patency different nitinol stent never perform except one study ; SMART versus Luminexx stent name SuperSL trial . LifeStent similar S.M.A.R.T . stent design consist peak-to-valley connected S-shaped bridge different less bridge ( 4 bridge vs. 6 bridge ) , large cell size stent end , large cell size S.M.A.R.T . On hand , Recent meta-analysis show efficaty cilostazol atherosclerotic femoropopliteal lesion proven . However , still specific data regard variety antiplatelet regimen implant femoropopliteal lesion limit . Upto date , literature , never never perform clinical trial optimal duration cilostazol use patient undergone stent implantation femoropopliteal lesion . Thus , The purpose study examine compare Primary patency stent fracture different two-nitinol stent ( S.M.A.R.T . CONTROL versus Lifestent ) femoropopliteal arterial lesion examine compare optimal duration cilostazol use .</brief_summary>
	<brief_title>Efficacy Self-Expanding Nitinol S.M.A.R.T CONTROL Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease</brief_title>
	<detailed_description>Five randomize , control trial fail demonstrate benefit stainless-steel stent angioplasty alone . The nitinol stent proven superior primary patency balloon angioplasty superficial femoral artery lesion . Recent stent design improvement focus decrease stent fracture rate negatively impact patency rate rearrange strut alignment . In vitro , Stefan et al . report difference stent design might play major role appearance stent strut fracture relate restenosis reocclusion . Also , several retrospective registry clinical study report stent fracture associate high risk in-stent restenosis reocclusion . In literature , however , prospective , randomize , control , clinical trial comparison stent fracture primary patency different nitinol stent never perform except one study ; SMART versus Luminexx stent name SuperSL trial ( lesion length 5-22 cm ) . Furthermore , Asian population , study type never perform . LifeStent similar S.M.A.R.T . stent design consist peak-to-valley connected S-shaped bridge different less bridge ( 4 bridge vs. 6 bridge ) , large cell size stent end , large cell size S.M.A.R.T . On hand , 2011 ESC guideline recommend dual antiplatelet therapy aspirin thienopyridine least one month recommend infrainguinal bare-metal-stent implantation . Recent meta-analysis show efficaty cilostazol atherosclerotic femoropopliteal lesion proven . However , still specific data regard variety antiplatelet regimen implant femoropopliteal lesion limit . Upto date , literature , never never perform clinical trial optimal duration cilostazol use patient undergone stent implantation femoropopliteal lesion . Thus , The purpose study examine compare Primary patency stent fracture different two-nitinol stent ( S.M.A.R.T . CONTROL versus Lifestent ) femoropopliteal arterial lesion examine compare optimal duration cilostazol use ( 6 month versus 12 month )</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Clinical criterion 1 . Age 20 year old 2 . Symptomatic peripheralartery disease ( Rutherford 2 6 ) ; moderate severe claudication ( Rutherford 23 ) , chronic critical limb ischemia pain rest ( Rutherford 4 ) , ischemic ulcer ( Rutherford 56 ) 3 . Patients sign informed consent Anatomical criterion 1 . Target lesion length &lt; 3 cm angiographic estimation 2 . Stenosis &gt; 50 % occlusive atherosclerotic lesion ipsilateral femoropopliteal artery 3 . Patent ( ≤50 % stenosis ) ipsilateral iliac artery concomitantly treatable ipsilateral iliac lesion ( ≤30 % residual stenosis ) , 4 . At least one patent ( le 50 % stenosed ) tibioperoneal runoff vessel . 1 . Disagree write informed consent 2 . Major bleed history within prior 2 month 3 . Known hypersensitivy contraindication follow medication : heparin , aspirin , clopidogrel contrast agent 4 . Acute limb ischemia 5 . Previous bypass surgery stenting ipsilateral femoropopliteal artery 6 . Untreated inflow disease ipsilateral pelvic artery ( 50 % stenosis occlusion ) 7 . Patients major amputation ( `` ankle '' amputation ) do , plan require 8 . Patients life expectancy &lt; 1 year due comorbidity 9. endstaged renal failure hemodialysis peritoneal dialysis 10 . Age &gt; 85 year</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>peripheral arterial disease</keyword>
	<keyword>atherosclerosis</keyword>
	<keyword>nitinol</keyword>
	<keyword>stent</keyword>
</DOC>